# A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

> **NCT03795558** · PHASE2 · COMPLETED · sponsor: **Prim. Priv. Doz. Dr. Daniel Cejka** · enrollment: 37 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Etelcalcetide

## Key facts

- **NCT ID:** NCT03795558
- **Lead sponsor:** Prim. Priv. Doz. Dr. Daniel Cejka
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2021-12-21
- **Final completion:** 2022-03-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795558, "A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03795558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*